News Release

Diseases of despair diagnoses increase in Pennsylvania

Peer-Reviewed Publication

Penn State

Diseases of Despair

audio: For the first time in nearly 100 years, life expectancy is decreasing in the United States. In this episode, Dr. Larry Sinoway discusses the decline and how it relates to the diseases of despair. He also discusses Penn State's efforts in the Commonwealth to address these diseases. Engage is a podcast of Penn State Clinical and Translational Science Institute. In each episode, you will learn about the research process and how Penn State is helping to improve the health of our neighbors and communities. view more 

Credit: Penn State Clinical and Translational Science Institute

Medical diagnoses involving alcohol-related disorders, substance-related disorders and suicidal thoughts and behaviors -- commonly referred to as diseases of despair -- increased in Pennsylvania health insurance claims between the years 2007 and 2018, according to researchers from Penn State Clinical and Translational Science Institute and Highmark Health Enterprise Analytics.

Princeton economists Anne Case and Angus Deaton proposed the concept of deaths of despair in 2015. Case and Deaton's research observed a decline in life expectancy of middle-aged white men and women between 1999 and 2015 -- the first such decline since the flu pandemic of 1918. They theorized that this decline is associated with the social and economic downturn in rural communities and small towns. These changes include loss of industry, falling wages, lower marriage rates, increasing barriers to higher education, an increase in one-parent homes and a loss of social infrastructure.

"It is theorized that these changes have fostered growing feelings of despair including disillusionment, precariousness and resignation in many peoples' lives," Daniel George, associate professor of humanities and public health sciences, Penn State College of Medicine, said. "Despair can trigger emotional, cognitive, behavioral and even biological changes, increasing the likelihood of diseases that can progress and ultimately culminate in deaths of despair."

With the commonwealth's considerable rural and small-town population, particularly around Penn State campuses, Penn State Clinical and Translational Science Institute led a research study to understand the rate of diseases of despair in Pennsylvania. Institute researchers collaborated with Highmark Health, one of the state's largest health insurance providers. Highmark provides employer-sponsored, individual, Affordable Care Act and Medicare plans.

Highmark Health's Enterprise Analytics team analyzed the claims of more than 12 million people on their plans from 2007 to 2018. Penn State did not have access to Highmark member data or individual private health information. Although the insurance claims included members from neighboring states, including West Virginia, Delaware, and Ohio, the majority of the claims were from Pennsylvania residents. Researchers reported their results in BMJ Open.

The researchers defined diseases of despair as diagnoses related to alcohol use, substance use and suicidal thoughts or behaviors. They searched the claims data for the International Classification of Diseases (ICD) codes related to these diagnoses. ICD codes form a standardized system maintained by the World Health Organization and are used in health records and for billing.

The researchers found that the rate of diagnoses related to diseases of despair increased significantly in the Highmark claims in the past decade. Nearly one in 20 people in the study sample was diagnosed with a disease of despair. Between 2009 and 2018, the rates of alcohol-, substance-, and suicide-related diagnoses increased by 37%, 94% and 170%. Following Case and Deaton's findings, the researchers saw the most substantial percentage increase in disease of despair diagnoses among men ages 35 to 74, followed by women ages 55 to 74 and 18 to 34.

The rate of alcohol-related diagnoses significantly increased among men and women ages 18 and over. The most dramatic increases were among men and women ages 55 to 74. Rates increased for men in this age group by 50% and 80% for women.

The rate of substance-related diagnoses roughly doubled for men and women ages 35 to 54 and increased by 170% in ages 55 to 74. In 2018, the most recent year of claims included in the study, rates of substance-use diagnoses were highest in 18-to-34-year-olds.

The rate of diagnoses related to suicidal thoughts and behaviors increased for all age groups. Among 18-to-34-year-olds, rates increased by at least 200%. The rate for all other age groups increased by at least 60%.

The type of insurance patients had also mattered. People with Medicare insurance had 1.5 times higher odds of having a disease of despair diagnosis and those with Affordable Care Act insurance had 1.3 times higher odds.

One increase stood out to researchers: among infants, substance-related diagnoses doubled.

"This increase was entirely attributable to neonatal abstinence syndrome and corresponded closely with increases in substance-related disorders among women of childbearing age," Emily Brignone, senior research scientist, Highmark Health Enterprise Analytics, said.

Neonatal abstinence syndrome occurs when a baby withdraws from substances, especially opioids, exposed to in the womb.

Future research can concentrate on identifying "hot spots" of diseases of despair diagnoses in the commonwealth to then study the social and economic conditions in these areas. With this data, researchers can potentially create predictive models to identify communities at risk and develop interventions.

"We found a broad view of who is impacted by increases in diseases of despair, which cross racial, ethnic and geographic groups," Jennifer Kraschnewski, professor of medicine, public health sciences and pediatrics, said. "Although originally thought to mostly affect rural communities, these increases in all middle-aged adults across the rural-urban continuum likely foreshadows future premature deaths."


National Center for Advancing Translational Science of the National Institutes of Health through Penn State Clinical and Translational Science Institute funded this research.

A podcast about this topic is available here.

Other researchers on this project were Lawrence Sinoway, director, Penn State Clinical and Translational Science Institute; Curren Katz and Robert Gladden, Highmark Health Enterprise Analytics; Charity Sauder, administrative director, Penn State Clinical and Translational Science Institute; and Andrea Murray, project manager, Penn State College of Medicine.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.